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• The tripeptide glutathione (GSH) is the quantita- 
tively most important cysteine derivative of low molecular 
weight and has numerous important cellular functions. 
Decreased plasma cysteine and cystine concentrations, 
decreased intracellular GSH levels, and increased plasma 
glutamate levels have been found in HIV-infected persons at 
all stages of the disease and in rhesus macaques within 2 
weeks after infection with the closely related simian immun- 
odeficiency virus SIVmac2$]- Elevated glutamate levels 
inhibit the membrane transport of cystine and aggravate 
thereby the consequences of the cysteine deficiency. 
Complementary experiments In laboratory animals have 
shown that glutathione potentiates T cell functions in vivo 
and in vitro. And studies with healthy human subjects have 
shown that persons with a combination of a higher than 
median plasma cystine and lower than median glutamate 
level have significantly more CD4~^~ T cells than persons with 
low cystine and high glutamate levels. On the basis of these 
findings we have proposed that the immunopathology of HIV 
infection may be largely the consequence of a virus-induced 
dysregulation of plasma amino acid concentrations. Studies 
on the mechanistic details revealed that the cysteine and intra- 
cellular glutathione deficiency may have several immuno- 
logically relevant consequences that affect the antigen pre- 
senting cells as well as the responding T lymphocytes. The 
redox regulation of the transcription factor NFkB accounts 
at least for some of the consequences 
INTRODUCTION 
• The acquired immunodeficiency syndrome 
(AIDS) is caused by the human immunodeficiency virus 
(HIV) which belongs to the family of non-transforming 
retroviruses. A closely related simian immunodeficiency 
virus (SIV) causes AIDS-like symptoms in rhesus 
macaques. The hallmarks of HIV infection are the severe 
depletion of the CD4
+
 T cell population and the cellular 
dysfunction that is seen in B cells and in all subsets of T 
cells. During the last 7 years, clinical studies and comple- 
mentary laboratory experiments have provided a large 
body of evidence suggesting that the HIV-induced 
immunopathology may be largely the consequence of a 
virus-induced cysteine deficiency (1-5). 
DYSREGULATION OF PLASMA AMINO ACIDS 
IN HIV-INFECT-ED PERSONS 
• The plasma thiol levels represent mainly cysteine 
and - to a minor extent - glutathione. Blood plasma of 
healthy human subjects contains about 15 pM thiol with a 
range of about 10-20 piM. HIV-infected persons were 
found to have, on the average, thiol levels of less than 10 
MM and in some cases less than 3 yM. This decrease of 
plasma cysteine and glutathione levels was associated with 
a significant decrease of intracellular glutathione both in 
the peripheral mononuclear cells and the monocyte pop- 
ulation (2). HIV-infected persons have also, on the aver- 
age, markedly elevated plasma glutamate levels (1-3). 
Some of the patients were found to have more than 5-fold 
the normal level. Glutamate levels are important in this 
context because extracellular glutamate inhibits competi- 
tively the membrane transport of cystine (6-8). Cell cul- 
ture experiments have shown that a 5-fold increase of extra- 
cellular glutamate concentrations causes a substantial 
decrease of intracellular cysteine and glutathione levels. 
THE EFFECT OF CYSTEINE AND 
GLUTATHIONE ON LYMPHO- CYTE 
FUNCTIONS 
• The importance of thiols (9JO) and especially of 
  
  
glutathione (11-13) for lymphocyte functions has been 
known for many years. The effect of glutathione in vivo on 
the induction of contact sensitivity in C3H mice is illus- 
Effect of glutathione on the induction of contact sensitivity 
 
Figure 1. Effect of glutathione on the induction of contact sen- 
sitivity. 
Two-month-old male C3Hmice were immunized by skin paint- 
ing with 6x10 \d 5% TNCB on the four footpads and two 
abdominal sites (day 0). The mice received also ip. injections 
of 1 ml BSS containing the indicated concentrations (GSH) 
on day 0 and on day 2. Five days after immunization, the mice 
were painted on both sides of the left ear with 2x10 \jl3% TNCB 
in acetone, and the are swelling index was determined 1 day 
later. 
trated in Fig.l. A similar immunopotentiating effect has 
been observed in mice with respect to the activation of 
cytotoxic T cells (12). Complementary studies in vitro in 
lymphocyte cultures with approximately physiological 
amino acid concentrations in graded concentrations of cys- 
teine have shown that several lymphocyte functions 
increase strongly with the extracellular supply of cysteine 
(2, 7, 13). Cysteine starvation causes under these condi- 
tions a marked depletion of intracellular glutathione lev- 
els and a strong decrease of DNA synthesis in T cell clones 
and in mitogenically stimulated ex vivo derived lympho- 
cytes, indicating that cysteine is indeed limiting for the 
magnitude of the proliferative T cell response. The 
decrease of the cysteine concentration in the plasma of 
HIV-infected persons is therefore expected to affect 
amongst others the IL-2 dependent proliferation of the T 
cells. . . . 
In addition, there is evidence that the consequences of the 
cysteine deficiency for a given T cell in the course of an 
immune response may depend on the nature of the stim- 
ulator cell. This has been illustrated amongst others in 
experiments with 2-mercaptoethanol (2-ME). This thiol 
compound is being added routinely to lymphocyte cultures 
by many immunologists, and Bannai and colleagues have 
Effect of 2 - mercaptoethanol on the cytotoxic T cell response 
against normal and UV - treated stimulator cells 
 
Figure 2. Effect of 2-mercaptoethanol on the cytotoxic T cell 
response against normal and UV-treated stimulator cells. 
7 
Spleen cells (2x10 ) from 2-month-old male C3H mice were 
incubated with 5x106 irradiated (1500 rad) and trinitro- 
phenylated C3H spleen cells with or without interleukin-2 (1,3 
U/ml) and with or without 3x10'* M 2-mercaptoethanol (2- 
ME) in RPMI1640 medium plus 10% fetal calf serum. Some 
of the cultures were stimulated with trinitrophenylated (CBA 
x BL/6) Fl cells, and some of the cultures were stimulated 
with trinitrophenylated cells which had been treated with UV- 
light for 15 min prior to the culture. 
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shown that it forms in cystine-containing culture medium 
a mixed cysteine/2-ME disulfide which is transported into 
lymphocytes much more effectively than the cysteine disul- 
fide cystine (14). The experiment in Fig.2 illustrates that 
spleen cells from C3H mice generate a profound cytotox- 
ic T cell activity against trinitrophenylated syngeneic tar- 
get cells if incubated with trinitrophenylated C3H spleen 
cells plus interleukin-2 (upper left panel), or with trinitro- 
phenylated semi-allogeneic C3H x DBA/2 stimulator cells 
in culture medium without 2-ME. When the stimulator cells 
are treated with UV-light, however, the respons in cultures 
without 2-ME is completely suppressed. In 2-ME-con- 
taining cultures all types of stimulator cells produce high 
and virtually indistinguishable cytotoxic T cell responses, 
indicating that the cysteine dependency is not only deter- 
mined by the responder cell per se but also by the nature 
of the antigen presenting stimulator cell (Fig.2). Since 
macrophages have a rather strong membrane transport 
activity for cystine and release reduced cysteine into the 
extracellular space, there is clearly the possibility that this 
cysteine delivering function may be compromised by UV- 
light (13,15). These findings may be relevant with respect 
to the exposure of HIV-infected patients to solar UV-irra- 
diation. 
CYSTEINE AS A REGULATORY MEDIATOR IN 
T CELL-MEDIAT- ED IMMUNE RESPONSES 
•  Macrophages are the antigen presenting cells par 
excellence. They process and present antigenic fragments 
in the context of their major histocompatibility antigens to 
the specific antigen receptors of the responding T limpho- 
cytes. In the process of antigenic stimulation, the T cell 
receptor binds to the antigen on the macrophage surface 
and causes thereby an intimate contact between the plas- 
ma membranes of the macrophage and the responding 
lymphocyte. Macrophages take this opportunity to deliv- 
er several regulatory mediators to the lymphocyte includ- 
ing the hormone-like cytokines interleukin-1 and TNF . In 
addition, we have provided evidence that cysteine plays a 
role similar to that of the cytokines, since it is also pro- 
duced by the macrophage at a variable and regulated rate 
and modulates the function of the responding T cell. This 
metabolic cooperation is based on several key facts. Firstly, 
most of the cysteine is present in the blood plasma main- 
ly in its oxidized form cystine. The cystine concentration 
in the plasma is equivalent to about 150 pM cysteine. T- 
lymphocytes, however, have only a very weak membrane 
transport activity for this relatively large amino acid (6,7) 
and can hardly take advantage of this relatively abundant 
extracellular source of cysteine. Lymphocytes have a rel- 
atively strong membrane transport activity for the smaller 
amino acid cysteine and other small neutral amino acids. 
However, the plasma concentration of cysteine is only 
about 15 ijM, which is one of the lowest concentrations 
among all protein forming amino acids. Macrophages, in 
contrast to lymphocytes, have a rather strong membrane 
transport activity for cystine (6,7) and take up more cys- 
tine than they need for their own metabolism. The excess 
is reduced intracellularly and released into the extracellu- 
lar space. This enables the macrophage to provide adja- 
cent lymphocytes with considerably higher extracellular 
concentrations of cysteine and to increase thereby their 
intracellular glutathione levels (13). Elevated extracellular 
concentrations of glutamate, as they are found in the plas- 
ma of HIV-infected persons, inhibit competitively the 
uptake of cystine and the release of cysteine into the extra- 
cellular space (13). 
THE REQUIREMENT OF PROOXIDANT 
STATES DURING THE ACTIVATION OF T 
LYMPHOCYTE 
• The most important physiological implication of 
the metabolic cooperation between macrophages and lym- 
phocytes may be that cysteine is delivered preferentially to 
those T cells that are about to be recruited into a specific 
immune response. This mechanism discriminates against 
bystander lymphocytes of unrelated specificities. 
Moreover, there are certain aspects of the immune 
response that appear to require prooxidant conditions. The 
induction of interleuken-2 production in T cells, for exam- 
ple, was found to be strongly augmented by hydrogen per- 
oxide (16). And Baeuerle and colleagues have show that 
the activation of the nuclear transcription factor NFicB is 
facilitated by reactive oxygen intermediates (ROI) (17,18). 
This transcription factor is involved in the inducible tran- 
scription of several immunologically relevant genes includ- 
ing the genes for the interleukin-2 receptor a-chain, tumor 




°gl°bulin and c-fos (19). 
The overexpression of TNFa, interleukin-2 receptor oc- 
chain cleavage products and J^-microglobulin that has 
been observed in HIV infected persons (20-25) thus may 
also be a consequence of the virus-induced cysteine defi- 
ciency. Last not least, the HIV-proviral DNA is also known 
to contain two binding sites for the transcription factor 
NFicB. As expected from the effect of cysteine on NFicB 
activity, we found that cysteine and N-acetyl-cysteine 
inhibit the replication of HIV in a dose-dependent fash- 
ion (26). 
CONCLUSIONS AMD CLINICAL 
IMPLICATIONS 
• Since certain aspects of T cell mediated immune 
responses require prooxidant conditions while others 
require antioxidant conditions and relatively high cysteine 
and glutathione levels, we hypothesized (i) that the func-   
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tion of the immune response may require a delicate bal- 
ance between prooxidant conditions, and (ii) that the meta- 
bolic cooperation between macrophages and lymphocytes 
may allow the limphocyte to switch from prooxidant to 
antioxidant conditions in the course of the immune 
response. This delicate balance between prooxidant and 
antioxidant conditions is apparently disturbed in HIV- 
infected persons by the HIV-induced cysteine deficiency 
and increased plasma glutamate levels. The cysteine defi- 
ciency and the decrease of intracellular glutathione levels 
are expected to affect primarily the IL-2-dependent pro- 
liferation and may contribute to the cellular dysfunction 
that is observed already in the very early stages of HIV 
infection. In addition, the cysteine deficiency is also expect- 
ed to cause an overactivation of functions that are favored 
by prooxidant states and may be responsible for an abnor- 
mal expression of certain cytokine genes that are under 
the control of NFicB. The overexpression of TNFoc is wide- 
ly believed to contribute to the progressive loss of muscle 
mass (cachexia) in these patients. 
In view of the important role of cysteine in the immune 
system and in view of the various consequences of a cys- 
teine deficiency for lymphocyte functions, we have pro- 
posed to consider cysteine or cysteine derivatives such as 
N-acetyl-cysteine (NAC) for the treatment of HIV-infect- 
ed persons. The first anecdotal observations by us and by 
others revealed that patients with manifest AIDS may 
improve substantially on NAC therapy but cannot be 
cured. Apparently, there are already too many irreversible 
metabolic deficiencies and immunological abnormalities 
in the late stages of the disease that cannot be corrected 
by this treatment. It is possible, however, that treatment of 
HIV-infected persons in the early stages of the disease with 
a cysteine derivative may prevent the devastating effects 
of HIV infection and the progression to full blown AIDS. 
About 90% of HIV-infected individuals are in the pre- 
AIDS stages. And N-acetyl-cysteine is a safe and inex- 
pensive drug with well documented pharmacology and 
pharmacokinetics. 
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